Engineering early immune resilience in islet transplantation

Area of Science:

• Immunology
• Transplantation Biology
• Regenerative Medicine

Background:

• Pancreatic islet transplantation aims to restore insulin independence in type 1 diabetes.
• The primary obstacle to successful islet transplantation is the rapid destruction of islets by the instant blood-mediated inflammatory reaction (IBMIR).
• IBMIR is a critical thrombo-inflammatory event that occurs within hours of transplantation, leading to graft loss even with optimal immunosuppression.

Purpose of the Study:

• To review recent advances in modulating the instant blood-mediated inflammatory reaction (IBMIR).
• To reposition IBMIR as a mechanistically understood and targetable process in islet transplantation.
• To outline how emerging technologies can create an immune-resilient microenvironment for durable islet transplantation.

Main Methods:

• Review of recent pharmacological and cell-intrinsic interventions targeting IBMIR.
• Analysis of biomaterial-based strategies for modulating the inflammatory response.
• Evaluation of extrahepatic transplant sites to mitigate IBMIR.
• Integration of diverse technological advancements for immune resilience.

Main Results:

• Recent advances show promise in modulating the IBMIR, transforming the ability to manage this early barrier.
• Pharmacological, cell-intrinsic, and biomaterial-based approaches, alongside strategic transplant sites, are key to overcoming IBMIR.
• These developments collectively contribute to building an immune-resilient microenvironment.

Conclusions:

• The instant blood-mediated inflammatory reaction (IBMIR) is a critical, targetable barrier in pancreatic islet transplantation.
• Converging technologies offer a path toward overcoming IBMIR and achieving durable, scalable islet transplantation.
• Establishing an immune-resilient microenvironment is essential for the clinical success of islet cell therapy in type 1 diabetes.